Peer-reviewed article
The prognostic value of AQP1 in hyperbilirubinemia related to ABO hemolytic disease of the newborn.
Zhenzhen Liu, Wei Shi, Jian Zhu, Lihong Liu ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This study examined whether a protein called AQP1 could predict how long newborns with ABO hemolytic disease need phototherapy treatment for high bilirubin levels. Researchers measured AQP1 levels in 168 newborns and tracked their recovery over 7 days. Newborns with higher AQP1 levels took longer to recover and were less likely to be cured within the week.
Key points
- AQP1 expression was significantly higher in newborns with ABO hemolytic disease compared to controls
- Newborns with high AQP1 had longer treatment times and lower cure rates within 7 days
- AQP1 levels were positively correlated with total bilirubin levels (R = 0.481, P < 0.001)
- High AQP1 expression was associated with 37.7% reduced likelihood of cure (HR = 0.623, P = 0.004)
- AQP1 could serve as a molecular marker to guide individualized treatment decisions
Limitations
The study does not specify the country or setting where it was conducted. The document provides no information about long-term outcomes beyond the 7-day follow-up period or whether the findings apply to other causes of neonatal hyperbilirubinemia.
Abstract
BACKGROUND: ABO hemolytic disease of the newborn (ABO-HDN) is a major cause of hyperbilirubinemia in neonates, often inducing significant elevation of serum bilirubin levels shortly after birth. PURPOSE: This study aimed to assess the prognostic value of Aquaporin 1 (AQP1) for hyperbilirubinemia in ABO-HDN as reflected by the duration of phototherapy, a key clinical indicator of disease severity and treatment response. METHODS: A retrospective cohort study was conducted, enrolling 168 neonates with ABO-HDN-related hyperbilirubinemia. Serum AQP1 expression was detected by RT-qPCR, and neonates were divided into a high-AQP1 expression group (n = 84) and a low-AQP1 expression group (n = 84) according to the median. All neonates were followed up for 7 days after the initiation of phototherapy, and a cure was defined as no total bilirubin (TBIL) rebound within 48 h after reaching the normal TBIL level. The cure rate was defined as the proportion of participants who achieved a cure within the 7‑day follow‑up period. RESULTS: The AQP1 expression in the ABO-HDN group was significantly higher than that in the control group. Additionally, the high-AQP1 group had a longer cure time and a lower cure rate within 7 days. Spearman analysis showed that AQP1 was positively correlated with TBIL (R = 0.481, P < 0.001). Cox regression analysis confirmed that high AQP1 expression was associated with a reduced cure rate (HR = 0.623, 95%CI: 0.449-0.861, P = 0.004). CONCLUSION: High-AQP1 expression was closely associated with prolonged treatment duration in ABO-HDN-related hyperbilirubinemia. AQP1 can serve as a potential molecular marker for prognostic assessment and individualized treatment guidance in such neonates.
Findings the Hub has extracted
Each claim below is labelled by its type of design and links back to this report.
- Intervention
- Measurement of serum AQP1 expression as a prognostic biomarker for treatment response and disease severity
- Population
- 168 neonates with ABO hemolytic disease-related hyperbilirubinemia (84 high-AQP1, 84 low-AQP1); compared against a control group of unaffected neonates
Key finding
High-AQP1 group had significantly longer cure time compared to low-AQP1 group
Liu et al. · PubMed (US National Library of Medicine) · 9 May 2026